0000000001123638

AUTHOR

E. Kersten

showing 1 related works from this author

In vivo models and decision trees for formulation development in early drug development: A review of current practices and recommendations for biopha…

2018

The ability to predict new chemical entity performance using in vivo animal models has been under investigation for more than two decades. Pharmaceutical companies use their own strategies to make decisions on the most appropriate formulation starting early in development. In this paper the biopharmaceutical decision trees available in four EFPIA partners (Bayer, Boehringer Ingelheim, Bristol Meyers Squibb and Janssen) were discussed by 7 companies of which 4 had no decision tree currently defined. The strengths, weaknesses and opportunities for improvement are discussed for each decision tree. Both pharmacokineticists and preformulation scientists at the drug discovery & development interf…

Chemistry PharmaceuticalDecision treePharmaceutical ScienceBiological Availability02 engineering and technology030226 pharmacology & pharmacyBiopharmaceutics03 medical and health sciences0302 clinical medicineDrug DevelopmentIn vivoNew chemical entityDrug DiscoveryAnimalsHumansBiological ProductsManagement scienceDrug discoveryDecision TreesGeneral Medicine021001 nanoscience & nanotechnologyClinical trialIdentification (information)BiopharmaceuticalDrug development0210 nano-technologyBiotechnologyEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct